Buzzing stock: Patent for pneumonia vaccine granted to Pfizer
DSIJ Intelligence / 24 Aug 2017
Pfizer Inc., a multinational drug maker, has been granted patent in India for its vaccine Prevenar 13, used for protection against pneumonia.
Pfizer Inc., a multinational drug maker, has been granted patent in India for its vaccine Prevenar 13, used for protection against pneumonia. The application for grant of patent in India for Prevenar 13 was filed by Wyeth LLC, USA in 2007. The Intellectual Property Office in India has granted the patent to Pfizer Inc., USA.
Pfizer Ltd. has been marketing this vaccine in India under a license given to it by Pfizer Inc., USA. Thus, this grant of patent means that Indian pharmaceutical companies will not be able to make the vaccine. Pfizer would exclusively sell it in India till 2026.
This vaccine protects people from 13 types of pneumococcal bacteria and the cost for a full vaccination course amounts to Rs 11,000 in India’s private market.
Meanwhile, Pfizer’s stock closed at Rs 1,808.95 on the BSE on Wednesday. Today, it has opened at a price of Rs 1,839, showing an upside of 1.7%.
Pfizer Inc. is a research-based global bio pharmaceutical company engaged in the discovery, development and manufacture of healthcare products.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.